Companies: 10,795·Total market cap: $144.5T
Vera Therapeutics, Inc.

Vera Therapeutics, Inc.

VERANASDAQHealthcare● Active
$32.40
+$0.11(+0.33%)
Market Cap$2.3B
P/E Ratio—
52W High$56.05
52W Low$19.066
SEC Filings

Vera Therapeutics, Inc. (VERA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001831828 · VERA · NASDAQ · as of Jun 8, 2026

Filing snapshot

454
Total Filings
8-K
Latest Form
2026-06-02
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001831828 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001193125-26-077442
Primary Document
vera-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001831828 · Accession 0001193125-26-077442

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-02Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-02
View
8-KCurrent Report
8-K
2026-05-26
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
ARSARS
ARS
2026-04-09
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-09
View
DEF 14AProxy Statement
DEF 14A
2026-04-09
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-01
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-27
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-25
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-03-11
View
8-KCurrent Report
8-K
2026-03-09
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-09
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-05
View
Showing 1–15 of 234 filingsForm 4 / 144 hidden· 454 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001831828  |  Exchange: NASDAQ · Healthcare

Vera Therapeutics, Inc. (NASDAQ: VERA) has submitted 454 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001831828, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Vera Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Vera Therapeutics, Inc. 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical VERA 10-K annual reports are available from 2021 through 2026.

Investors researching Vera Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
PHVS SEC Filings →CLDX SEC Filings →HRMY SEC Filings →IMNM SEC Filings →QURE SEC Filings →NUVB SEC Filings →ABCL SEC Filings →VRDN SEC Filings →
→ VERA Financials→ VERA Earnings→ VERA Insider Trades

Frequently Asked Questions

VERA SEC Filings · 8 questions

Vera Therapeutics, Inc. (VERA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 454 filings and access original documents at no cost. Vera Therapeutics, Inc.'s CIK is 0001831828.

VERA SEC filingsVera Therapeutics, Inc. SEC documentsfind VERA 10-K